IGF1R 可预测高级别浆液性上皮性卵巢癌患者的生存情况，并与 hCtr1 水平相关。

IGF1R predicts better survival in high-grade serous epithelial ovarian cancer patients and correlates with hCtr1 levels.

机构信息

Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, Maharashtra, India.

Homi Bhabha National Institute, Anushakti Nagar, Mumbai 400094, Maharashtra, India.

出版信息

Biomark Med. 2019 May;13(7):511-521. doi: 10.2217/bmm-2018-0311. Epub 2019 May 29.

DOI:10.2217/bmm-2018-0311

PMID:31140856

Abstract

To evaluate the potential of IGF1R as a prognostic marker for high-grade serous ovarian cancer (HGSOC) patients. The expression levels of and drug transporters (, ) were measured longitudinally in chemo-naive and chemo-treated tumor samples from 19 HGSOC patients, and their correlation with the clinical outcome was examined. expression was significantly upregulated in treated tumor samples, which positively correlated with levels. Patients with metastatic tumors with expression higher than median showed better overall survival (median not reached) and disease-free survival (26.7 months) than those with less than median expression (overall survival: 27.5 months [p = 0.029]; disease-free survival: 11.9 months [p = 0.014]). IGF1R prognosticates prolonged survival in HGSOC patients, possibly due to its positive correlation with hCtr1.

摘要

评估 IGF1R 作为高级别浆液性卵巢癌 (HGSOC) 患者预后标志物的潜力。在 19 名 HGSOC 患者的化疗初治和化疗后肿瘤样本中，纵向测量和药物转运蛋白（、）的表达水平，并检查其与临床结果的相关性。在治疗后的肿瘤样本中表达显著上调，与水平呈正相关。与表达中位数以下的患者相比，表达高于中位数的转移性肿瘤患者的总生存期（未达到中位数）和无病生存期（26.7 个月）更好（总生存期：27.5 个月[P=0.029]；无病生存期：11.9 个月[P=0.014]）。IGF1R 可能由于与 hCtr1 呈正相关，可预测 HGSOC 患者的生存延长。